Eli Lilly Diabetes Drugs

Eli Lilly shares drop

Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand

Eli Lilly cut its 2024 revenue guidance, saying demand for its obesity and diabetes drugs had not met its lofty expectations. Eli Lilly expects about $3.5 billion in revenue for its diabetes treatment Mounjaro and $1.

Barron's on MSN · 17h

Eli Lilly Stumbled But Weight-Loss Drugs Will Continue to Fuel Markets. Here’s Why and 5 Other Things to Know Today.

SEC sues Elon Musk over Twitter purchase, Microsoft says businesses should get quantum ready in 2025, and more news to start your day.

YAHOO!Finance · 1d

Eli Lilly Cuts Q4 Revenue Guidance, Expects Around $5.5 Billion Sales From Weight Loss/Diabetes Drugs, Stock Tanks

Eli Lilly and Co (NYSE: LLY) announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, representing a 32% growth compared to the previous year versus the consensus of $45.

Zepbound, Lilly and Mounjaro

STAT · 9h

Eli Lilly is considering offering more Zepbound doses in vials at lower cost

Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning to compounding pharmacies that make cheaper copies of Zepbound, since the branded treatment has been too costly and, up until recently, has been in shortage.

Barron's on MSN · 1d

Eli Lilly’s Zepbound and Mounjaro Sales Missed Estimates Again. The Wobble’s Looking Serious.

The results are an uncomfortable echo of late October 2024, when Mounjaro and Zepbound missed by similar margins. Those results unsettled investors, setting off a three-week sello

Zacks.com on MSN · 11h

NVO, VKTX Stocks Fall as Lilly's Zepbound, Mounjaro Sales Slow Down

24/7 Wall St. on MSN14h

Down 23%, Is This Dividend Giant a Buy After GLP-1 Sales Miss?

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

5hon MSN

City of Columbus sues drug companies over insulin prices

Columbus joins the states of Arkansas, California, Kansas, Kentucky, Minnesota and Mississippi and other cities and counties ...

Eli Lilly Stock Falls on Slower Sales Growth of Anti-Obesity Drug

Eli Lilly shares fell after the drugmaker warned that sales of its hot diabetes and anti-obesity drugs are growing more slowly than expected. Lilly now expects fourth-quarter sales of $3.5 billion for ...

City Schools sues diabetes medication drug makers

Baltimore's school board joined districts across the country in suing drug makers over the skyrocketing costs of diabetes ...

17hon MSN

Baltimore City school system sues drug companies over allegedly inflated price of insulin

The Baltimore City Board of School Commissioners is suing Eli Lilly and Co., UnitedHealth Group, CVS and several other drug ...

Eli Lilly's obesity drug gets Medicare coverage for sleep apnea

Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...

GlobalData on MSN17h

JP Morgan 2025: Eli Lilly misses 2024 revenue estimate by $400m

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.

Lilly blames slower-than-expected growth for 2024 sales miss

The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...

Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday

Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results